Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

• Published in: BioMed research international 2023, Vol.2023 (1), p.1496072-1496072
• Main Authors: Sánchez, Yamirka, Concepción, Martha L., Amador, Yohan, Piriz, Angel, Rabassa, René, Leyva, Ariel, Arguelles, Odalys, Leblanch, Lisett, Moret, Sheyla, Rivero, Gilberto, Vasallo, Ana L., Martorell, Beatriz, Guerra, Pedro P., Valls, Ana R., Sánchez, Lisset, Saumell, Yaimarelis
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - pathology; Adverse events; Anemia; Antiangiogenics; Anticancer properties; Antigen presentation; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Apoptosis; Biomedical research; Cancer therapies; Cell cycle; Chemotherapy; Clinical trials; Confidence intervals; Cytokines; Cytotoxicity; Deoxycytidine - therapeutic use; Disease; Disease control; Gemcitabine; Growth factors; Health services; Humans; Ligands; Lymphocytes; Metastases; Metastasis; Pancreas; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - pathology; Patients; Prospective Studies; Statistical analysis; Survival; Terminology; Treatment Outcome; Tumors
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2023/1496072

Background. Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. Methods. A prospective, nonrandomized, uncontrolled, open-label, and multicenter clinical trial was conducted to evaluate the safety and effectiveness of nimotuzumab combined with gemcitabine as first-line treatment in unresectable locally advanced or metastatic pancreatic tumors in a real-world condition. Adverse events, their intensity, severity, and causality were determined using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0). Median overall survival, median progression-free survival, and 1- and 2-year survival rates were determined by using the Kaplan-Meier. Results. 69 patients were included. The proportion of related serious adverse events was 1.2%. The most frequent adverse events were nausea (10%), anemia (8%), and abdominal pain (8%). Objective response was achieved in 18.5% of the patients and disease control in 43.1%. Patients with locally advanced disease achieved a median overall survival of 16.36 months (95% CI; 14.35-18.38); 1- and 2-year survival rates of 72.2 and 29.2 months, respectively; a median progression-free survival of 9.6 months (95% CI; 4.91-14.20); and a 1-year progression-free survival rate of 39%. Patients with metastatic disease achieved a median survival of 6.23 months (95% CI; 4.32-8.13); 1- and 2-year survival rates of 18.1 and 3.0 months, respectively; a median progression-free survival of 7.6 months (95% CI; 6.08-9.90); and 1- and 2-year PFS rates of 20.5 and 5.1 months, respectively. Conclusions. Nimotuzumab combined with gemcitabine represents a safe and effective first-line treatment option for patients with advanced pancreatic adenocarcinoma in real-world conditions. Survival benefits were increased in those patients who received 8 or more doses of nimotuzumab. This trial is registered with RPCEC00000245 in the Cuban Registry of Clinical Trials, part of the World Health Organization’s International Clinical Trials Registry Platform (ICTRP).